162
Registered trials
54
Recruiting
100
Completed trials
85
Sponsors
26
Countries
Phase III:
52
Phase II/III:
3
Phase II:
82
Phase I/II:
14
Phase III/IV:
2
Phase IV:
5
Phase I (Other):
3
Other:
1
Oversight events:
6 serious breaches
11 temporary halts
2 urgent safety measures
1 unexpected event
2 corrective measures
across 13 trials
View oversight register →
Indications tested
Non-small cell lung cancer
16
Non-small cell lung cancer stage III
9
Small cell lung cancer extensive stage
7
Cholangiocarcinoma
6
Triple negative breast cancer
5
Small cell lung cancer
4
Hepatocellular carcinoma
4
Non-small cell lung cancer metastatic
3
Non-small cell lung cancer stage IIIB
3
Bladder cancer
3
Non-small cell lung cancer stage IIIA
3
Non-small cell lung cancer stage II
3
Sponsors using this IMP
AstraZeneca AB
49
Unicancer
8
ETOP IBCSG Partners Foundation
4
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
4
Intergroupe Francophone De Cancerologie Thoracique
4
Merck Sharp & Dohme LLC
4
Institut Jules Bordet
3
IRCCS Istituto Nazionale Tumori Fondazione Pascale
3
Amgen Inc.
2
Amsterdam UMC Stichting
2
Astrazeneca Farmaceutica Spain S.A.
2
Centre Leon Berard
2
All trials — page 3
162 total-
DRUP trial Recruiting
Showing 49–72 of 162 trials